US 12,030,935 B2
Anti-PDGF-B antibodies and pharmaceutical composition thereof
Yinglin Gao, Upper Saddle River, NJ (US); Scott Macdonnell, New Milford, CT (US); Bharathi Sundaram, Yonkers, NY (US); Jee Kim, Ardsley, NY (US); Isabella Del Priore, Smithtown, NY (US); Jake Megna, Pine Bush, NY (US); Qin Ruan, Yorktown Heights, NY (US); and Lori C. Morton, Chappaqua, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Jan. 25, 2022, as Appl. No. 17/583,930.
Claims priority of provisional application 63/141,030, filed on Jan. 25, 2021.
Prior Publication US 2022/0242943 A1, Aug. 4, 2022
Int. Cl. A61K 39/395 (2006.01); A61P 9/12 (2006.01); A61P 43/00 (2006.01); C07K 16/22 (2006.01); C07K 16/24 (2006.01)
CPC C07K 16/22 (2013.01) [A61P 9/12 (2018.01); A61P 43/00 (2018.01); C07K 16/24 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01)] 9 Claims
 
1. An isolated human monoclonal antibody, or antigen-binding fragment thereof, that binds specifically to human Platelet-Derived Growth Factor Subunit B (PDGF-B), wherein the antibody, or antigen-binding fragment thereof, comprises:
(a) an HCDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 4;
(b) an HCDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 6;
(c) an HCDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 8;
(d) an LCDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 12;
(e) an LCDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 14; and
(f) an LCDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 16.